Additional file 3 of PTK2-associated gene signature could predict the prognosis of IPF
figure
posted on 2024-08-14, 09:31 authored by Anlin Feng, Yesenia Moreno Caro, Colin Gardner, Garrett Grischo, Ying Liang, Praveen D. Wickremasinghe, Michaela Polmann, Mrinalini Kala, Timothy Marlowe, Stephen M. Black, Kenneth S. Knox, Ting WangAdditional file 3: Figure S2. Defactinib (FAK inhibitor) reduced fibrotic markers in DHLF-IPF cells. A) Defactinib reduced fibrotic markers, B) pY397-FAK, and alpha smooth muscle actin (α-SMA), in DHLF-IPF cells, C) cellular morphology of DHLF-IPF cells.
Funding
National Heart, Lung, and Blood Institute
History
Usage metrics
Categories
Keywords
smooth muscle actinfocal adhesion kinaseevaluating clinical outcomesvaluable therapeutic targetfatal lung diseasefak ), producedptk2 inhibitor defactinibpredict disease prognosisrisk group acrossinduced fak activationgene signature basedptk2 molecular signaturepredict ipf prognosisipf patients comparedblood ptk2 levelsmolecular targetfak activationptk2 levelsactivation levelsgene signaturelung tissuesfak mayblood cells196 ptk2poor prognosisipf patientsipf developmentvalidation cohortsstudy aimedreduce tgfβprognostic biomarkermicroarray datalimited sensitivitylesional fibroblastsincrease αimmune pathwaysimmune cellshealthy controlsfunctional enrichmentfindings suggestedassociated genes11 genes
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC